News | March 09, 2021
Vivimed Labs receives products approvals from Uzbekistan
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Bharat Biotech expects to share further details of the trial results as additional data become available.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
The jump in profit is due to the better performance of the API business.
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
Subscribe To Our Newsletter & Stay Updated
